The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir
Open accessAbstract
Dolutegravir is a second-generation integrase strand transfer inhibitor (INSTI) currently under review by the US Food and Drug Administration for marketing approval. The in vitro, protein-adjusted 90 % inhibitory concentration (IC90) of dolutegravir for wild-type virus is 0.064 μg/ml, and it retains in vitro anti-HIV 1 activity across a broad range of viral phenotypes that are known to confer resistance to the currently marketed INSTIs, raltegravir and elvitegravir. Dolutegravir has a terminal elimination half-life of 13–14 h and maintains concentrations over the in vitro, protein-adjusted IC90 for more than 30 h following a single dose. Additionally, dolutegravir has low inter-subject variability compared with raltegravir and elvitegravir. A plasma exposure–response relationship has been well described, with antiviral activity strongly correlating with trough concentrations. Phase III trials have assessed the antiviral activity of dolutegravir compared with efavirenz and raltegravir in antiretroviral (ARV)-naive patients and found that dolutegravir achieved more rapid and sustained virologic suppression in both instances. Additionally, studies of dolutegravir activity in patients with known INSTI-resistant mutations have been favourable, indicating that dolutegravir retains activity in a variety of INSTI-resistant phenotypes. Much like currently marketed INSTIs, dolutegravir is very well tolerated. Because dolutegravir inhibits the renal transporter organic cation transporter 2, reduced tubular secretion of creatinine leads to non-progressive increases in serum creatinine. These serum creatinine increases have not been associated with a decreased glomerular filtration rate or progressive renal impairment. Dolutegravir’s major and minor metabolic pathways are uridine diphosphate glucuronosyltransferase 1A1 and cytochrome P450 (CYP)-3A4, respectively, and it neither induces nor inhibits CYP isoenzymes. Thus dolutegravir has a modest drug interaction profile. However, antacids significantly decrease dolutegravir plasma exposure and should be separated by 2 h before, or 6 h after, a dolutegravir dose. In summary, dolutegravir is the first of the second-generation INSTIs and exhibits a predictable pharmacokinetic profile and a well-defined exposure–response relationship. Dolutegravir retains activity despite the presence of some class-resistant mutations and achieves rapid and sustained virologic suppression in ARV-naive and ARV-experienced patients. Clinically, dolutegravir is poised to become a commonly used component of antiretroviral regimens.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-12_part_2-199806151-00003 · Cited by 5,209
Ward, B. A., Gorski, J. C., Jones, D. R., Hall, S. D., Flockhart, D. A., & Desta, Z. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.049601 · Cited by 593
Raffi, F., Rachlis, A., Stellbrink, H.-J., Hardy, W. D., Torti, C., Orkin, C., Bloch, M., Podzamczer, D., Pokrovsky, V., Pulido, F., et al. (2013) · The Lancet · doi:10.1016/s0140-6736(12)61853-4 · Cited by 548
In Vitro Antiretroviral Properties of S/GSK1349572, a Next-Generation HIV Integrase Inhibitor
Kobayashi, M., Yoshinaga, T., Seki, T., Wakasa-Morimoto, C., Brown, K. W., Ferris, R., Foster, S. A., Hazen, R. J., Miki, S., Suyama-Kagitani, A., et al. (2011) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01209-10 · Cited by 382
Eron, J. J., Clotet, B., Durant, J., Katlama, C., Kumar, P., Lazzarin, A., Poizot-Martin, I., Richmond, G., Soriano, V., Ait-Khaled, M., et al. (2013) · The Journal of Infectious Diseases · doi:10.1093/infdis/jis750 · Cited by 311
van Lunzen, J., Maggiolo, F., Arribas, J. R., Rakhmanova, A., Yeni, P., Young, B., Rockstroh, J. K., Almond, S., Song, I., Brothers, C., et al. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(11)70290-0 · Cited by 301
DeJesus, E., Berger, D., Markowitz, M., Cohen, C., Hawkins, T., Ruane, P., Elion, R., Farthing, C., Zhong, L., Cheng, A. K., et al. (2006) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/01.qai.0000233308.82860.2f · Cited by 270 · cited 1×
“Dolutegravir’s coefficients of variation (CVs) are\30 % for both the area under the plasma concentration–time curve (AUC) and the maximum plasma concentration (Cmax) in single- and multiple-dose studies, whereas raltegravir and elvitegravir demonstrate AUC CVs of 212 and 33–72 %, respectively [1, 14].”
BackgroundHare, S., Smith, S. J., Métifiot, M., Jaxa-Chamiec, A., Pommier, Y., Hughes, S. H., & Cherepanov, P. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073189 · Cited by 264
Reese, M. J., Savina, P. M., Generaux, G. T., Tracey, H., Humphreys, J. E., Kanaoka, E., Webster, L. O., Harmon, K. A., Clarke, J. D., & Polli, J. W. (2013) · Drug Metabolism and Disposition · doi:10.1124/dmd.112.048918 · Cited by 254
Min, S., Song, I., Borland, J., Chen, S., Lou, Y., Fujiwara, T., & Piscitelli, S. C. (2010) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.00842-09 · Cited by 244
Cited by
Llibre, J. M., Hung, C.-C., Brinson, C., Castelli, F., Girard, P.-M., Kahl, L. P., Blair, E. A., Angelis, K., Wynne, B., Vandermeulen, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33095-7 · Cited by 358
Next generation organofluorine containing blockbuster drugs
Han, J., Remete, A. M., Dobson, L. S., Kiss, L., Izawa, K., Moriwaki, H., Soloshonok, V. A., & O’Hagan, D. (2020) · Journal of Fluorine Chemistry · doi:10.1016/j.jfluchem.2020.109639 · Cited by 313
Glucocorticoid induced adrenal insufficiency
Prete, A., & Bancos, I. (2021) · BMJ · doi:10.1136/bmj.n1380 · Cited by 155
Pharmacokinetics of a Long-Acting Nanoformulated Dolutegravir Prodrug in Rhesus Macaques
McMillan, J., Szlachetka, A., Slack, L., Sillman, B., Lamberty, B., Morsey, B., Callen, S., Gautam, N., Alnouti, Y., Edagwa, B., et al. (2018) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.01316-17 · Cited by 32
Metadata
- Authors
- Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M.
- Venue
- Clinical Pharmacokinetics
- Published
- 2013-07-04
- Volume
- 52
- Issue
- 11
- Pages
- 981-994
- ISSN
- 0312-5963 (ISSN-L)
- 1179-1926
- OpenAlex
- W2085120686
- Cited by
- 298
- References
- 25
- FWCI
- 10.55
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir. https://app.cochat.ai/papers/10.1007/s40262-013-0093-2
- The paper
- Cottrell, M. L., Hadzic, T., & Kashuba, A. D. M. (2013). Clinical Pharmacokinetic, Pharmacodynamic and Drug-Interaction Profile of the Integrase Inhibitor Dolutegravir. Clinical Pharmacokinetics. https://doi.org/10.1007/s40262-013-0093-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.